Avalo Therapeutics Expands IL-1β Pipeline with Next-Gen AVTX-010, IND Planned H1 2027
AVTX has more than doubled off its 52-week low of $4.46.
Summary
Avalo Therapeutics announced the advancement of AVTX-010, a long-acting, next-generation anti-IL-1β monoclonal antibody, into its pipeline. This strategic move builds on the recent positive Phase 2 results for their lead IL-1β asset, abdakibart, and follows a significant $405 million financing in May that provides funding into 2029. AVTX-010 aims to offer less frequent dosing, potentially improving patient convenience and adherence in hidradenitis suppurativa and other inflammatory disorders, strengthening the company's intellectual property and market potential in the IL-1β pathway. The company expects to submit an Investigational New Drug (IND) application for AVTX-010 in the first half of 2027.
At the time of this announcement, AVTX was trading at $14.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $767.5M. The 52-week trading range was $4.46 to $24.27. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.